Actively Recruiting
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Led by Fujian Cancer Hospital · Updated on 2026-03-03
42
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.
CONDITIONS
Official Title
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years, any gender
- Pathologically confirmed rectal cancer with liver metastases (stage M1)
- Karnofsky Performance Status of 70 or higher
- Adequate organ function with no contraindications to radiotherapy or immunotherapy
- Microsatellite stability or proficient mismatch repair status (MSS/pMMR)
- No prior chemotherapy or other anti-tumor treatments before study entry
- No prior immunotherapy
- Ability to comply with the study protocol during the study period
- Signed written informed consent
You will not qualify if you...
- Pregnant or lactating women
- Diagnosis of signet ring cell carcinoma
- History of other cancers within the past 5 years, except cured skin cancer and cervical carcinoma in situ
- Uncontrolled epilepsy, central nervous system disorders, or psychiatric conditions affecting consent or medication compliance
- Active significant cardiac disease or recent myocardial infarction within 12 months
- Organ transplant recipients on immunosuppressive therapy or long-term steroid use
- Presence of autoimmune diseases
- Severe uncontrolled infections or other serious comorbidities
- Abnormal baseline blood counts or liver/kidney function tests beyond specified limits
- Known deficiency of dihydropyrimidine dehydrogenase (DPD)
- Allergy to any investigational drug components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fuzhou First General Hospital
Fuzhou, Fujian, China, 350004
Not Yet Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
Research Team
H
Hui Li, MD
CONTACT
J
Jinluan Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here